Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Tuesday, December 9, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, advanced practice providers, nurses, and other HCPs involved in the treatment and management of early-stage breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Integrate biomarkers into clinical practice to stratify recurrence risk and tailor multidisciplinary treatment strategies for patients with early-stage HR+/HER2- breast cancer.
- Develop individualized treatment plans for patients with early-stage HR+/HER2- breast cancer based on latest clinical trial evidence and guideline recommendations.
- Implement evidence-based strategies to monitor and manage adverse events associated with treatments for early-stage HR+/HER2- breast cancer to ensure optimal patient outcomes and quality of life.
Tiffany A. Traina, MD, FASCO
Associate Professor of Medicine
Weill Cornell Medicine
Associate Attending Physician
Vice Chair, Oncology Department of Medicine
Section Head, Triple Negative Breast Cancer Clinical
Research Program
Memorial Sloan Kettering Cancer Center
New York, NY
Kevin Kalinsky, MD, MS, FASCO
Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Louisa and Rand Glenn Family Chair in Breast Cancer
Research
Director, Glenn Family Breast Center
Director, Division of Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, GA
Mark E. Robson, MD, FASCO
Chief, Breast Medicine Service
Memorial Sloan Kettering Cancer Center
New York, NY
Rebecca Shatsky, MD
Professor of Medicine
Breast Medical Oncology Team Leader
Director of Breast Cancer Clinical Trials
Director of Inflammatory and Triple Negative Breast Cancer Program
University of California, San Diego
San Diego, CA
Full faculty information and disclosures are available by reviewing the program workbook, linked here.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.